Yang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yang Li has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Lingling Chen
School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
2 shared publications - Shulei Jia
School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
2 shared publications - Guiliang Zheng
School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
1 shared publication - Henan Cao
Tianjin Medical University, China
1 shared publication - Henan Cao
School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
1 shared publication - Siqi Sun
Tianjin Medical University, China
1 shared publication
Latest Publications
- Open Access
- 2 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 567
In Silico Design and Characterization of a Multi-Epitope Vaccine Candidate Against Mycoplasma pneumoniae Using a Reverse Vaccinology Strategy
Mycoplasma pneumoniae (M. pneumoniae) is the crucial factor of global acquired respiratory infections. Currently, there are no specific disease modification treatments or vaccines available, and the vaccine development for this pathogen lags behind due to the complexity and variability of its antigens. A novel vaccine with broad-spectrum characteristics is essential to provide comprehensive protection against continuously evolving wild-type strains. Here, a broad-spectrum muti-epitope vaccine against M. pneumoniae had been designed through immunoinformatics methods. To ensure its broad-spectrum, we generated consistent sequences from all the antigen proteins of different strains, and then identified potential T cell epitopes. The multi-epitope vaccine (MEV) of M. pneumoniae incorporated 16 CTLs and 7 HTLs from the HMW1–3 and p1 adhesin proteins, which comprised 458 amino acids with adjuvant. The vaccine evaluation showed that the MEV had ideal physicochemical properties, high antigenicity, high immunogenicity, and was non-toxic. Furthermore, there was a strong and stable binding interaction between this vaccine and the toll-like receptors, which could be supported by the normal mode analysis. Finally, codon optimization resulted in the optimal GC content and higher CAI value. The vaccine candidate is expected to induce strong cellular immune responses and may provide protective immunity against the pathogen. We provided a novel in silico vaccine design strategy for vaccine design, which could provide a technical framework for the development of vaccines against other pathogens.
- 2 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 567
Open AccessIn Silico Design and Characterization of a Multi-Epitope Vaccine Candidate Against Mycoplasma pneumoniae Using a Reverse Vaccinology Strategy
Mycoplasma pneumoniae (M. pneumoniae) is the crucial factor of global acquired respiratory infections. Currently, there are no specific disease modification treatments or vaccines available, and the vaccine development for this pathogen lags behind due to the complexity and variability of its antigens. A novel vaccine with broad-spectrum characteristics is essential to provide comprehensive protection against continuously evolving wild-type strains. Here, a broad-spectrum muti-epitope vaccine against M. pneumoniae had been designed through immunoinformatics methods. To ensure its broad-spectrum, we generated consistent sequences from all the antigen proteins of different strains, and then identified potential T cell epitopes. The multi-epitope vaccine (MEV) of M. pneumoniae incorporated 16 CTLs and 7 HTLs from the HMW1–3 and p1 adhesin proteins, which comprised 458 amino acids with adjuvant. The vaccine evaluation showed that the MEV had ideal physicochemical properties, high antigenicity, high immunogenicity, and was non-toxic. Furthermore, there was a strong and stable binding interaction between this vaccine and the toll-like receptors, which could be supported by the normal mode analysis. Finally, codon optimization resulted in the optimal GC content and higher CAI value. The vaccine candidate is expected to induce strong cellular immune responses and may provide protective immunity against the pathogen. We provided a novel in silico vaccine design strategy for vaccine design, which could provide a technical framework for the development of vaccines against other pathogens.
- Open Access
- 28 May 2025
- Published by MDPI AG in Preprints.org
Broad-Spectrum Multi-Epitope Vaccine Against Mycoplasma pneumoniae Based on Reverse Vaccinology
Mycoplasma pneumoniae (M. pneumoniae) is the crucial factor of global acquired respiratory infections. Currently, there are no specific disease modification treatments or vaccines available, and the vaccine development for this pathogen delays behind due to the complexity and variability of its antigens. A novel vaccine designed with wide-spectrum characteristics is crucial to offer comprehensive safeguards against the continuously mutated wild-type strains. Here, a broad-spectrum T-cell epitope vaccine against M. pneumoniae was designed by using a consensus sequence approach. The multi-epitope vaccine incorporated 16 CTLs and 7 HTLs from the HMW1-3 and p1 proteins, which was comprised of 329 amino acids without adjuvant. It was predicted to be soluble and non-allergenic with high population coverage, high antigenicity and immunogenicity. This vaccine was predicted to effectively bind to the toll-like receptors in natural immunity. In addition, simulations created by computers suggested that the vaccine might trigger genuine immune responses in human immune system. To sum up, it could be a candidate vaccine guard against the infection of M. pneumoniae.
- 28 May 2025
- Published by MDPI AG in Preprints.org
Open AccessBroad-Spectrum Multi-Epitope Vaccine Against Mycoplasma pneumoniae Based on Reverse Vaccinology
Mycoplasma pneumoniae (M. pneumoniae) is the crucial factor of global acquired respiratory infections. Currently, there are no specific disease modification treatments or vaccines available, and the vaccine development for this pathogen delays behind due to the complexity and variability of its antigens. A novel vaccine designed with wide-spectrum characteristics is crucial to offer comprehensive safeguards against the continuously mutated wild-type strains. Here, a broad-spectrum T-cell epitope vaccine against M. pneumoniae was designed by using a consensus sequence approach. The multi-epitope vaccine incorporated 16 CTLs and 7 HTLs from the HMW1-3 and p1 proteins, which was comprised of 329 amino acids without adjuvant. It was predicted to be soluble and non-allergenic with high population coverage, high antigenicity and immunogenicity. This vaccine was predicted to effectively bind to the toll-like receptors in natural immunity. In addition, simulations created by computers suggested that the vaccine might trigger genuine immune responses in human immune system. To sum up, it could be a candidate vaccine guard against the infection of M. pneumoniae.